AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03832816 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo vapor (distilled water)
Study NCT03832816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaporized THC alone
Description: Acute exposure to vaporized THC
Study NCT03832816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaporized CBD alone
Description: Acute exposure to vaporized CBD
Study NCT03832816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaporized CBD with THC
Description: Acute exposure to vaporized CBD with THC
Study NCT03502941 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 6.3 g of EAAs mixture and whey protein isolate
Description: A single dose of the mixture of EAAs/whey
Study NCT03502941 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 12.6 g of EAAs mixture and whey protein isolate
Description: A double dose of the mixture of EAAs/whey
Study NCT03502941 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 12.6 g of whey protein isolate
Description: Whey protein isolate alone, which is an equal amount to the double dose of the mixture of EAAs/whey
Study NCT01810289 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: START
Description: INTERVENTION: START is clinic-level (not individual-patient) intervention to catalyze the process of ART initiation among HIV-infected adults who meet CD4-based criteria for combination ART (e.g., adults with a CD4 T cell level \< 350/ul). The three START components are: (1) real-time point-of-care CD4 testing using the Alere PIMA platform to ascertain treatment eligibility in real time at first presentation to care, (2)targeted knowledge transfer(i.e., dissemination) of recent scientific evidence regarding effects rapid ART initiation on survival to front line health care workers; and 3)feedback and reporting to clinic and providers. There three components represent empirically validated steps in the PRECEED implementation model.~This intervention will be implemented at all Makerere Joint AIDS Program (MJAP) clinics in Kampala and Mbarara districts in a step-wedge design.
Study NCT00128362 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radio-guided sentinel node biopsy
Study NCT00128362 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Axillary sampling
Study NCT01351714 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: D3 resection
Description: Radical D3 resection of the right colon through the use of preoperative MDCT angiography
Study NCT03898752 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 3
Description: Omega 3: 1g daily for 3 months CoQ10: 100 mg daily for 3 months Multivitamin: 1 normal multivitamin tablet daily for 3 months
Study NCT01228838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGX-1998
Description: Capsaicin topical liquid to be applied for 5 minutes one time only.
Study NCT01228838 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Liquid
Description: Placebo topical liquid to be applied for 5 minutes one time only.
Study NCT03290703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0853
Description: Participants will receive different formulations of GDC-0853 tablet.
Study NCT03290703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Participants will receive rabeprazole 20 mg twice daily (BID) for three days prior to GDC-0853 administration and a single dose coadministered with GDC-0853.
Study NCT02437721 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: infant formula containing folic acid
Study NCT02437721 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: infant formula containing MTHF
Study NCT00949949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Given PO
Study NCT00949949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT00949949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT04530708 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic radiotherapy
Description: 36 Gy to the primary lung tumor and present mediastinal node metastases after three months of medical treatment.
Study NCT02731846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 100 mcg + Vilanterol 25 mcg
Description: Dry white powder delivered via ELLIPTA inhaler (2 strips with 30 blisters each, first containing fluticasone furoate 100 mcg per blister and second containing Vilanterol 25 mcg per blister), administered as one inhalation of FF/VI (100/25 mcg) once-daily in the morning
Study NCT04235478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Product: triamcinolone and saline
Description: a mixture of 3 mL 0.09%saline and 2 mL 80 mg triamcinolone (kenacort-a)
Study NCT05812456 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Estimation of Shear Bond Strength
Description: Measuring shear bond strength between the different bracket brands and the enamel will be estimated by aiming the edge of the blade of the universal testing machine at bracket-enamel interface. The force required to debond each bracket will be registered in Newtons (N), and converted to Megapascals by dividing the force registered in newtons on each bracket base area (mm2).~After bond failure, the brackets and the enamel surfaces will be examined and assessed for the amount of adhesive remaining on the bracket bases by using digital microscope at 35x magnification. this will identify the site of bond failure.
Study NCT05812456 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Estimation of Shear Bond Strength
Description: Measuring shear bond strength between the different bracket brands and the enamel will be estimated by aiming the edge of the blade of the universal testing machine at bracket-enamel interface. The force required to debond each bracket will be registered in Newtons (N), and converted to Megapascals by dividing the force registered in newtons on each bracket base area (mm2).~After bond failure, the brackets and the enamel surfaces will be examined and assessed for the amount of adhesive remaining on the bracket bases by using digital microscope at 35x magnification. this will identify the site of bond failure.
Study NCT02539121 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture needles
Study NCT03097094 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Male dog
Description: Male dog extract
Study NCT03097094 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Female dog
Description: Female dog extract
Study NCT00352560 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irbesartan
Description: Tablets, Oral, 300 mg, once daily, 30 days.
Study NCT00352560 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, 0 mg, once daily, 30 days.
Study NCT01314573 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sprint interval exercise
Description: 3 session per week of exercise on a exercise cycle ergometer. Each session involves 30s of maximal exercise followed by 4.5 min of easy cycling at 10W. This is repeated 4 times at each exercise session.
Study NCT01314573 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maximal continuous exercise
Description: 3 sessions per week of an exercise intervention involving maximal cycling until the participant has completed an amount of work equivalent to a sprint interval training session. This exercise lasts between 3 and 3.5 minutes.
Study NCT01954550 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cycling exercise
Description: An exercise interventionist will guide and supervise participants to participate in moderate-intensity cycling on recumbent stationary cycles for 20-50 minutes, 3 times a week for 6 months.
Study NCT01954550 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Range of motion/stretching exercise
Description: An exercise interventionist will guide and supervise participants to participate in low-intensity range of motion/stretching exercise for 20-50 minutes, 3 times a week for 6 months.
Study NCT00748501 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SB-509
Description: Intramuscular injection of 60 mg of SB-509. Two doses on Day 0 and Day 90.
Study NCT02339272 — intervention group
Intervention type: OTHER
Intervention: non interventional
Study NCT03766633 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Liver volumetry of the graft on CT
Description: Preoperative liver volumetry using the CT images of the potential living liver donors.
Study NCT01673867 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study NCT01673867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Study NCT02559193 — intervention group
Intervention type: OTHER
Intervention: Observational study, data collection only trial.
Description: Data collection only trial design.
Study NCT04593225 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU + multicomponent treatment VIRTUAL SFCAMINA
Description: Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients (approx. in the same order): - Pain neuroscience education (15 min.) - Cognitive restructuring (15 min.) - Mindfulness techniques (15 min.) - Physical exercise(15 min.) - Treatment as Usual (TAU) Standard pharmacological treatment usually provided to patients with SFC.
Study NCT04593225 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Treatment-as-Usual (TAU) consisted of the prescribed drugs adapted to the symptomatic profile of each patient and basic face to face and written advice on PNE and aerobic exercise adapted to the physical capacities of the patients at the beginning of the study.
Study NCT01473836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Metronidazole will be administered at a dose of 500 mg TID (or QID for refractory or severe infection) for 3 to 14 days, in principle. Treatment duration can be prolonged up to 21 days based on subject's condition.
Study NCT01473836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftriaxone sodium
Description: Ceftriaxone sodium will be administered at a daily dose of 2 g (strength) when metronidazole is administered TID or at a daily dose of 4 g (strength) when metronidazole is administered QID.
Study NCT03875885 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CONNECT
Description: A novel web-based intervention with input from an advisory panel of cancer caregivers, oncology providers, and psychosocial oncology professionals empowering caregivers with needs to seek services by providing education about the benefits of supportive care resources, systematically identifying their unmet needs, and connecting them with tailored supportive care resources.
Study NCT03875885 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CONTROL
Description: This group will receive a generic resource list. The generic resource list will be printed for participants and emailed to them, if participants have an email address.
Study NCT04043260 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Advisor Pro
Description: The DreaMed Advisor Pro software is a proprietary algorithm, designed to provide a comprehensive analysis of individual diabetes data which consists of glucose levels and insulin delivery history. the Advisor Pro algorithm identifies glucose patterns and their possible causes, which may hamper the patient's glucose control, and recommend on adjustment to the patient-specific insulin treatment profiles as well as suggestions for personalized diabetes management tips (such as timing of meal boluses, bolus delivery compliance and personalized glucose targets).
Study NCT02048891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH agonist trigger
Study NCT02048891 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hCG trigger
Study NCT03558776 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: linseed oil
Description: linseed oil and defined background diet
Study NCT03558776 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: linseed oil
Description: linseed oil and defined background diet
Study NCT01084746 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PC-based tailored intervention
Description: Patients will receive a tailored interactive PC-based intervention at a freestanding kiosk.
Study NCT01084746 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Printed educational materials
Description: Patients will receive generic printed educational materials about CRCS in the PEC when they arrive at the Main Campus for their appointment.
Study NCT00643227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clarithromycin extended release (ER)
Description: 7 days of clarithromycin extended release (ER), 1.0 g by mouth once daily
Study NCT00643227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azithromycin SR
Description: Single, 2.0 g oral dose of azithromycin sustained release (SR) by mouth once daily
Study NCT03069807 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community/Primary Care
Description: The treatment of Latent Tuberculosis Infection (LTBI) in the community by General Practitioners (Family Doctors) and Pharmacists
Study NCT03069807 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hospital/TB Clinic
Description: The treatment of Latent Tuberculosis Infection (LTBI) in the Hospital TB Clinic by specialist doctors and nurses
Study NCT01191229 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Tecnis one-piece MF IOL
Description: 25 patients to be implanted after cataract surgery
Study NCT01191229 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Crystalens AO
Description: 25 patients that are previously implanted
Study NCT03539471 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: interview, Tridimensional Personality Questionnaire
Description: interview of the residents about 15-20 minutes, then use Tridimensional Personality Questionnaire
Study NCT04506372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perioperative withdrawal of angiotensin converting enzyme inhibitors and angiotenin receptor blockers
Description: Withdrawal from 24 hours before surgery until 24-48 hours after surgery. The ACEI/ARB medication is resumed on the second or third day after surgery, as soon as the clinical condition allows based on judgement by the attending physician.
Study NCT04506372 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Blood draw
Description: Blood will be drawn to measure creatinin and troponin: once before surgery, on the first and second postoperative day, and within 4-8 weeks after surgery
Study NCT04506372 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood draw
Description: Blood will be drawn to measure creatinin and troponin: once before surgery, on the first and second postoperative day, and within 4-8 weeks after surgery
Study NCT04506372 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diary to register drug adherence
Description: To register medication adherence, patients will be asked to fill out their medication intake (of ACEI/ARB) in a diary from a week before surgery until surgery.
Study NCT04506372 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diary to register drug adherence
Description: To register medication adherence, patients will be asked to fill out their medication intake (of ACEI/ARB) in a diary from a week before surgery until surgery.
Study NCT04506372 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Quality of life questionnaire
Description: Patients are asked to fill out a quality of life questionnaire (EQ-5D) before surgery and at three months after surgery
Study NCT04506372 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality of life questionnaire
Description: Patients are asked to fill out a quality of life questionnaire (EQ-5D) before surgery and at three months after surgery
Study NCT04506372 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WHODAS questionnaire
Description: Patients are asked to fill out a questionnaire about disabilities (WHO Disability Assessment Schedule 2.0) before surgery and at three months after surgery
Study NCT04506372 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WHODAS questionnaire
Description: Patients are asked to fill out a questionnaire about disabilities (WHO Disability Assessment Schedule 2.0) before surgery and at three months after surgery
Study NCT01389817 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near-infrared light-emitting diode (NIR-LED) therapy (Med Light 630 PRO (Medical Devices Inc.))
Description: Subjects will be exposed to light emitted from a Med Light 630 PRO (Medical Devices Inc.) at a wavelength of 630 nm (+/-15nm) with an exposure of 4 J/cm2. This is accomplished by applying the 50 mW/cm2 LED-generated light to the closed study eye for 80 seconds. Treatments involve application of the LED-generated light for 80 seconds, twice daily.
Study NCT00105469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AzaSite
Description: AzaSite ophthalmic solution; one topical drop to the infected eye or eyes twice daily (in the morning and at bedtime) on Days 1 and 2 followed by once daily (in the morning between 7 and 10am) on Days 3 through 5.
Study NCT00105469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin
Description: Tobramycin ophthalmic solution; one topical drop to the infected eye or eyes four times daily at 4 to 6 hour intervals (first dose in the morning between 7 and 10am) for 5 days.
Study NCT02532491 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Initial dose: 10 mg.
Study NCT02532491 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Initial dose: 2 mg.
Study NCT02720471 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Locoregional anesthesia
Description: classical analgesia by ultrasound guidance by blocks of the femoral and cutaneous nerves side of the thigh
Study NCT02720471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peroperative infiltration of local anesthetics
Description: peroperative infiltration of local anesthetics
Study NCT02467868 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MYL-1401H
Description: During each chemotherapy cycle MYL-1401H (6 mg) is administered s.c. 24 hours after chemotherapy.
Study NCT02467868 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Neulasta
Description: During each chemotherapy cycle Neulasta (6 mg) is administered s.c. 24 hours after chemotherapy.
Study NCT04344509 — intervention group
Intervention type: OTHER
Intervention: Bacterial species isolated
Description: in the respiratory specimen
Study NCT03833245 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: The patient navigation (PN) intervention will initiate following participant recruitment. It is important to note that PN sessions do not strictly coincide with specific weeks of pregnancy since the women can be recruited up to ≤25 weeks of gestation. The prenatal portion of the intervention includes 10 sessions delivered within approximately 14 weeks. The postnatal portion of the intervention will be delivered as 4 sessions over 8 weeks. Women who complete the intervention before delivery will receive regular calls/texts until delivery wherein the navigator will encourage and reinforce abstinence and treatment retention. All contact will be reported by staff in a patient contact log developed for the study that will be used to quantify level of patient contact.
Study NCT02183194 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lutonix Paclitaxel Drug Coated Balloon
Study NCT04922775 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: conventional taping
Description: Participants will accept conventional taping before muscle fatigue exercise.
Study NCT02731846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umeclidinium 62.5 mcg
Description: Dry white powder delivered via ELLIPTA inhaler (1 strip with 30 blisters containing Umeclidinium 62.5 mcg, administered as one inhalation once-daily in the morning
Study NCT02731846 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo ELLIPTA inhaler
Description: Placebo will be administered via ELLIPTA inhaler. Dry white powder administered as one inhalation each morning (1 strip with 30 blisters containing placebo)
Study NCT02731846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol/Salbutamol
Description: Albuterol/salbutamol will be administered via metered-dose inhaler (MDI) with a spacer as needed throughout the study as a rescue medication
Study NCT03817970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granisetron
Description: An antiemetic regimen containing granisetron 2 mg oral or IV.
Study NCT03817970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: An antiemetic regimen containing ondansetron 8 mg oral or IV.
Study NCT03817970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: An antiemetic regimen containing palonosetron 0.25 mg IV.